UCSB Arts & Lectures and the Cancer Foundation of Santa Barbara co-present Dr. Jennifer Doudna, CRISPR Gene Editing and the ...

News about biofuels sometimes mentions used cooking oil as a feedstock, but if these substances contain animal fat, they can ...

CRISPR, the gene-editing technology, has been one of the major breakthroughs in biology in the last two decades. And while ...

CREME is a virtual laboratory that allows scientists to simulate specific decreases in gene activity. It offers a powerful new tool for identifying and understanding important parts of the genome. And ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $49.49, denoting a -0.2% change from the preceding trading day.

Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end ...

CRISPR Therapeutics AG (CRSP) closed the latest trading day at $49.59, indicating a -0.56% change from the previous session's end. The stock's change was less than the S&P 500's daily loss of 0.29%.

Mission Bio explains how single-cell multiomics can help researchers overcome the challenges of heterogeneous editing ...

With antibiotics losing their effectiveness, one company is turning to gene editing and bacteriophages—viruses that infect bacteria—to combat infections.

CRISPR Therapeutics' first therapy is called Casgevy. It treats sickle cell disease (SCD) and beta thalassemia, both rare inherited illnesses that affect the function of a person's red blood cells. It ...

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

View full profile. Learn about our editorial policies. Like the human immune system, bacteria learn from past infections. CRISPR sequences—short snippets of DNA from previous viruses—guide destructive ...